Post-EHA 2026 MDS Highlights

Featuring presentations & discussions on selected MDS abstracts from the 31st Congress of the European Hematology Association (EHA).  

Chair: Amer Zeidan | Moderators: Yasmin Abaza & María Díez Campelo

Preliminary Agenda (subject to change)

Session 1: Updates in low-risk MDS management  

Luspatercept (luspa) initiated at the maximum-approved dose in patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS) who require transfusions: Primary analysis from MAXILUS (Abstract S173) | Speaker: Matteo Della Porta

Early versus delayed ESA in lower-risk non-transfusion-dependent MDS: Final Phase III EPO-PRETAR results on transfusion dependence and erythroid response (Abstract S171) | Speaker: Sophie Park

Ofirnoflast, a first-in-class NEK7 inhibitor, induces robust transfusion independence and multilineage hematological improvement in lower-risk myelodysplastic syndrome (LR-MDS): Phase 2 results (Abstract S174) | Speaker: Varun Bafna

Roxadustat improves transfusion independence in LR-MDS patients with anemia and high transfusion burden and in ring sideroblast positive and negative disease: Post-hoc analysis of MATTERHORN study (Abstract PF668) | Speaker: Amer Zeidan

Panel discussion 

Session 2: Recent progress in the management of AML and high-risk MDS

Translational insights and clinical efficacy with bexmarilimab and azacitidine in HR-MDS in the BEXMAB Phase 1/2 study (Abstract PF663) | Speaker: Mika Kontro

CPX-351 versus standard of care as bridging to allo-HCT in patients with higher-risk myelodysplastic neoplasms or oligoblastic acute myeloid leukemia: Results of the randomized Phase 2 PALOMA study (Abstract S170) | Speaker: TBC

Phase II study of cladribine, low dose cytarabine and venetoclax, alternating with azacitidine and venetoclax, in higher risk myelodysplastic syndromes (Abstract PS1759) | Speaker: TBC

Safety, tolerability, and efficacy of mesutoclax (ICP-248) in combination with azacitidine in patients with myeloid malignancies (Abstract 6506 [Presented at ASCO 2026]) | Speaker: TBC

Panel discussion 

Session 3: Latest in TP53-mutated MDS 

Functional TP53 phenotype score refines prognostic stratification in monoallelic TP53-mutated myelodysplastic neoplasms beyond allelic state (Abstract S172) | Speaker: Alexander Streuer 

Allogeneic HSCT for TP53-aberrant myeloid neoplasms: Real-world outcomes from a Scandinavian multicentre cohort (Abstract S273) | Speaker: Anders Myhre

Panel discussion 

Session 4: Advances in prognostics & latest RWE 

Refining prognostic stratification for sAML post-allo–HSCT: Validation of ELN 2022 and predominant role of MDS-related cytogenetics (Abstract S271) | Speaker: Nan Yang

VEXAS prognostic score: Personalized machine learning derived risk stratification model (Abstract PS1758) | Speaker: Tariq Kewan

Hypomethylating agents with or without venetoclax in treatment-naïve myelodysplastic syndromes with excess blasts: Results from a large retrospective cohort (Abstract PS1760) | Speaker: Alex Bataller

Panel discussion 

Conclusions and webinar close